Keeley Ellen C, Boura Judith A, Grines Cindy L
Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9047, USA.
Lancet. 2006 Feb 18;367(9510):579-88. doi: 10.1016/S0140-6736(06)68148-8.
Facilitated percutaneous coronary intervention for ST-segment-elevation myocardial infarction (STEMI) is defined as the use of pharmacological substances before a planned immediate intervention, to improve coronary patency. We undertook a meta-analysis of randomised controlled trials (published and unpublished) to compare facilitated and primary percutaneous coronary intervention.
We identified 17 trials of patients with STEMI assigned to facilitated (n=2237) or primary (n=2267) percutaneous coronary intervention. We identified short-term outcomes (up to 42 days) of death, stroke, non-fatal reinfarction, urgent target vessel revascularisation, and major bleeding. Grade 3 flow rates for prethrombolysis and post-thrombolysis in myocardial infarction (TIMI) were also analysed.
The facilitated approach resulted in a greater than two-fold increase in the number of patients with initial TIMI grade 3 flow, compared with the primary approach (832 patients [37%] vs 342 [15%], odds ratio 3.18, 95% CI 2.22-4.55); however, final rates did not differ (1706 [89%] vs 1803 [88%]; 1.19, 0.86-1.64). Significantly more patients assigned to the facilitated approach than those assigned to the primary approach died (106 [5%] vs 78 [3%]; 1.38, 1.01-1.87), had higher non-fatal reinfarction rates (74 [3%] vs 41 [2%]; 1.71, 1.16-2.51), and had higher urgent target vessel revascularisation rates (66 [4%] vs 21 [1%]; 2.39, 1.23-4.66); the increased rates of adverse events seen with the facilitated approach were mainly seen in thrombolytic-therapy-based regimens. Facilitated intervention was associated with higher rates of major bleeding than primary intervention (159 [7%] vs 108 [5%]; 1.51, 1.10-2.08). Haemorrhagic stroke and total stroke rates were higher in thrombolytic-therapy-containing facilitated regimens than in primary intervention (haemorrhagic stroke 15 [0.7%] vs two [0.1%], p=0.0014; total stroke 24 [1.1%] vs six [0.3%], p=0.0008).
Facilitated percutaneous coronary intervention offers no benefit over primary percutaneous coronary intervention in STEMI treatment and should not be used outside the context of randomised controlled trials. Furthermore, facilitated interventions with thrombolytic-based regimens should be avoided.
ST段抬高型心肌梗死(STEMI)的易化经皮冠状动脉介入治疗定义为在计划立即进行的介入治疗前使用药物,以改善冠状动脉通畅情况。我们对随机对照试验(已发表和未发表的)进行了一项荟萃分析,以比较易化和直接经皮冠状动脉介入治疗。
我们确定了17项针对STEMI患者的试验,这些患者被分配接受易化(n = 2237)或直接(n = 2267)经皮冠状动脉介入治疗。我们确定了短期结局(至42天),包括死亡、中风、非致命性再梗死、紧急靶血管血运重建和大出血。还分析了心肌梗死溶栓前和溶栓后3级血流速度(TIMI)。
与直接治疗方法相比,易化治疗方法使初始TIMI 3级血流患者数量增加了两倍多(832例患者[37%]对342例[15%],优势比3.18,95%CI 2.22 - 4.55);然而,最终比率没有差异(1706例[89%]对1803例[88%];1.19,0.86 - 1.64)。分配接受易化治疗方法的患者死亡人数明显多于分配接受直接治疗方法的患者(106例[5%]对78例[3%];1.38,1.01 - 1.87),非致命性再梗死率更高(74例[3%]对41例[2%];1.71,1.16 - 2.51),紧急靶血管血运重建率更高(66例[4%]对21例[1%];2.39,1.23 - 4.66);易化治疗方法中不良事件发生率的增加主要见于基于溶栓治疗的方案。易化干预比直接干预的大出血发生率更高(159例[7%]对108例[5%];1.51,1.10 - 2.08)。含溶栓治疗的易化方案中出血性中风和总中风发生率高于直接干预(出血性中风15例[0.7%]对2例[0.1%],p = 0.0014;总中风24例[1.1%]对6例[0.3%],p = 0.0008)。
在STEMI治疗中,易化经皮冠状动脉介入治疗并不优于直接经皮冠状动脉介入治疗,不应在随机对照试验之外使用。此外,应避免使用基于溶栓方案的易化干预。